APO Research
Talk to an analyst

APO RESEARCH · REPORT

IL-17 Inhibitors for Psoriasis

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global IL-17 Inhibitors for Psoriasis Market Analysis and Forecast 2026-2032

29 December 2025192 pages

Choose your research edition.

Industry ResearchIL-17 Inhibitors for Psoriasis Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal IL-17 Inhibitors for Psoriasis Industry Growth and Trends Forecast to 203299 pages · $3,450 USDMarket StructureGlobal IL-17 Inhibitors for Psoriasis Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal IL-17 Inhibitors for Psoriasis Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal IL-17 Inhibitors for Psoriasis Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global IL-17 Inhibitors for Psoriasis market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for IL-17 Inhibitors for Psoriasis is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for IL-17 Inhibitors for Psoriasis is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for IL-17 Inhibitors for Psoriasis is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for IL-17 Inhibitors for Psoriasis is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of IL-17 Inhibitors for Psoriasis include UCB, Kyowa Kirin, LEO Pharma, Ortho Dermatologics, Jiangsu Hengrui Pharmaceuticals, Eli Lilly, Novartis and Chongqing Genrix Biopharmaceutical, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for IL-17 Inhibitors for Psoriasis, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of IL-17 Inhibitors for Psoriasis, also provides the sales of main regions and countries. Of the upcoming market potential for IL-17 Inhibitors for Psoriasis, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the IL-17 Inhibitors for Psoriasis sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global IL-17 Inhibitors for Psoriasis market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for IL-17 Inhibitors for Psoriasis sales, projected growth trends, production technology, application and end-user industry.

IL-17 Inhibitors for Psoriasis Segment by Company

UCB

Kyowa Kirin

LEO Pharma

Ortho Dermatologics

Jiangsu Hengrui Pharmaceuticals

Eli Lilly

Novartis

Chongqing Genrix Biopharmaceutical

IL-17 Inhibitors for Psoriasis Segment by Type

Ixekizumab

Secukinumab

Xeligekimab

Vunakizumab

Brodalumab

Bimelizumab

Other

IL-17 Inhibitors for Psoriasis Segment by Application

Hospital and Clinic

Pharmacy

Other

IL-17 Inhibitors for Psoriasis Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global IL-17 Inhibitors for Psoriasis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of IL-17 Inhibitors for Psoriasis and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of IL-17 Inhibitors for Psoriasis.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of IL-17 Inhibitors for Psoriasis in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of IL-17 Inhibitors for Psoriasis manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, IL-17 Inhibitors for Psoriasis sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global IL-17 Inhibitors for Psoriasis Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Ixekizumab Major Manufacturers Table 3. Secukinumab Major Manufacturers Table 4. Xeligekimab Major Manufacturers Table 5. Vunakizumab Major Manufacturers Table 6. Brodalumab Major Manufacturers Table 7. Bimelizumab Major Manufacturers Table 8. Other Major Manufacturers Table 9. Global IL-17 Inhibitors for Psoriasis Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 10. Hospital and Clinic Major Manufacturers Table 11. Pharmacy Major Manufacturers Table 12. Other Major Manufacturers Table 13. IL-17 Inhibitors for Psoriasis Industry Trends Table 14. IL-17 Inhibitors for Psoriasis Industry Drivers Table 15. IL-17 Inhibitors for Psoriasis Industry Opportunities and Challenges Table 16. IL-17 Inhibitors for Psoriasis Industry Restraints Table 17. Global IL-17 Inhibitors for Psoriasis Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global IL-17 Inhibitors for Psoriasis Revenue by Region (2021-2026) & (US$ Million) Table 19. Global IL-17 Inhibitors for Psoriasis Revenue by Region (2027-2032) & (US$ Million) Table 20. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Region (2021-2026) Table 21. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Region (2027-2032) Table 22. Global IL-17 Inhibitors for Psoriasis Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (Units) Table 23. Global IL-17 Inhibitors for Psoriasis Sales by Region (2021-2026) & (Units) Table 24. Global IL-17 Inhibitors for Psoriasis Sales by Region (2027-2032) & (Units) Table 25. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Region (2021-2026) Table 26. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Region (2027-2032) Table 27. Global IL-17 Inhibitors for Psoriasis Revenue by Manufacturers (US$ Million) & (2021-2026) Table 28. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Manufacturers (2021-2026) Table 29. Global IL-17 Inhibitors for Psoriasis Sales by Manufacturers (US$ Million) & (2021-2026) Table 30. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Manufacturers (2021-2026) Table 31. Global IL-17 Inhibitors for Psoriasis Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 32. Global IL-17 Inhibitors for Psoriasis Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 33. Global IL-17 Inhibitors for Psoriasis Key Manufacturers Manufacturing Sites & Headquarters Table 34. Global IL-17 Inhibitors for Psoriasis Manufacturers, Product Type & Application Table 35. Global IL-17 Inhibitors for Psoriasis Manufacturers' Establishment Date Table 36. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 37. Global IL-17 Inhibitors for Psoriasis by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 38. Global IL-17 Inhibitors for Psoriasis Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global IL-17 Inhibitors for Psoriasis Revenue by Type (2021-2026) & (US$ Million) Table 40. Global IL-17 Inhibitors for Psoriasis Revenue by Type (2027-2032) & (US$ Million) Table 41. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Type (2021-2026) Table 42. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Type (2027-2032) Table 43. Global IL-17 Inhibitors for Psoriasis Sales by Type 2021 VS 2025 VS 2032 (Units) Table 44. Global IL-17 Inhibitors for Psoriasis Sales by Type (2021-2026) & (Units) Table 45. Global IL-17 Inhibitors for Psoriasis Sales by Type (2027-2032) & (Units) Table 46. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Type (2021-2026) Table 47. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Type (2027-2032) Table 48. Global IL-17 Inhibitors for Psoriasis Price by Type (2021-2026) & (US$/Unit) Table 49. Global IL-17 Inhibitors for Psoriasis Price by Type (2027-2032) & (US$/Unit) Table 50. Global IL-17 Inhibitors for Psoriasis Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global IL-17 Inhibitors for Psoriasis Revenue by Application (2021-2026) & (US$ Million) Table 52. Global IL-17 Inhibitors for Psoriasis Revenue by Application (2027-2032) & (US$ Million) Table 53. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Application (2021-2026) Table 54. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Application (2027-2032) Table 55. Global IL-17 Inhibitors for Psoriasis Sales by Application 2021 VS 2025 VS 2032 (Units) Table 56. Global IL-17 Inhibitors for Psoriasis Sales by Application (2021-2026) & (Units) Table 57. Global IL-17 Inhibitors for Psoriasis Sales by Application (2027-2032) & (Units) Table 58. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Application (2021-2026) Table 59. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Application (2027-2032) Table 60. Global IL-17 Inhibitors for Psoriasis Price by Application (2021-2026) & (US$/Unit) Table 61. Global IL-17 Inhibitors for Psoriasis Price by Application (2027-2032) & (US$/Unit) Table 62. UCB Company Information Table 63. UCB Business Overview Table 64. UCB IL-17 Inhibitors for Psoriasis Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 65. UCB IL-17 Inhibitors for Psoriasis Product Portfolio Table 66. UCB Recent Development Table 67. Kyowa Kirin Company Information Table 68. Kyowa Kirin Business Overview Table 69. Kyowa Kirin IL-17 Inhibitors for Psoriasis Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Kyowa Kirin IL-17 Inhibitors for Psoriasis Product Portfolio Table 71. Kyowa Kirin Recent Development Table 72. LEO Pharma Company Information Table 73. LEO Pharma Business Overview Table 74. LEO Pharma IL-17 Inhibitors for Psoriasis Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. LEO Pharma IL-17 Inhibitors for Psoriasis Product Portfolio Table 76. LEO Pharma Recent Development Table 77. Ortho Dermatologics Company Information Table 78. Ortho Dermatologics Business Overview Table 79. Ortho Dermatologics IL-17 Inhibitors for Psoriasis Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Ortho Dermatologics IL-17 Inhibitors for Psoriasis Product Portfolio Table 81. Ortho Dermatologics Recent Development Table 82. Jiangsu Hengrui Pharmaceuticals Company Information Table 83. Jiangsu Hengrui Pharmaceuticals Business Overview Table 84. Jiangsu Hengrui Pharmaceuticals IL-17 Inhibitors for Psoriasis Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Jiangsu Hengrui Pharmaceuticals IL-17 Inhibitors for Psoriasis Product Portfolio Table 86. Jiangsu Hengrui Pharmaceuticals Recent Development Table 87. Eli Lilly Company Information Table 88. Eli Lilly Business Overview Table 89. Eli Lilly IL-17 Inhibitors for Psoriasis Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Eli Lilly IL-17 Inhibitors for Psoriasis Product Portfolio Table 91. Eli Lilly Recent Development Table 92. Novartis Company Information Table 93. Novartis Business Overview Table 94. Novartis IL-17 Inhibitors for Psoriasis Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Novartis IL-17 Inhibitors for Psoriasis Product Portfolio Table 96. Novartis Recent Development Table 97. Chongqing Genrix Biopharmaceutical Company Information Table 98. Chongqing Genrix Biopharmaceutical Business Overview Table 99. Chongqing Genrix Biopharmaceutical IL-17 Inhibitors for Psoriasis Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Chongqing Genrix Biopharmaceutical IL-17 Inhibitors for Psoriasis Product Portfolio Table 101. Chongqing Genrix Biopharmaceutical Recent Development Table 102. North America IL-17 Inhibitors for Psoriasis Revenue by Type (2021-2026) & (US$ Million) Table 103. North America IL-17 Inhibitors for Psoriasis Revenue by Type (2027-2032) & (US$ Million) Table 104. North America IL-17 Inhibitors for Psoriasis Sales by Type (2021-2026) & (Units) Table 105. North America IL-17 Inhibitors for Psoriasis Sales by Type (2027-2032) & (Units) Table 106. North America IL-17 Inhibitors for Psoriasis Sales Price by Type (2021-2026) & (US$/Unit) Table 107. North America IL-17 Inhibitors for Psoriasis Sales Price by Type (2027-2032) & (US$/Unit) Table 108. North America IL-17 Inhibitors for Psoriasis Revenue by Application (2021-2026) & (US$ Million) Table 109. North America IL-17 Inhibitors for Psoriasis Revenue by Application (2027-2032) & (US$ Million) Table 110. North America IL-17 Inhibitors for Psoriasis Sales by Application (2021-2026) & (Units) Table 111. North America IL-17 Inhibitors for Psoriasis Sales by Application (2027-2032) & (Units) Table 112. North America IL-17 Inhibitors for Psoriasis Sales Price by Application (2021-2026) & (US$/Unit) Table 113. North America IL-17 Inhibitors for Psoriasis Sales Price by Application (2027-2032) & (US$/Unit) Table 114. North America IL-17 Inhibitors for Psoriasis Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 115. North America IL-17 Inhibitors for Psoriasis Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 116. North America IL-17 Inhibitors for Psoriasis Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 117. North America IL-17 Inhibitors for Psoriasis Sales by Country (2021 VS 2025 VS 2032) & (Units) Table 118. North America IL-17 Inhibitors for Psoriasis Sales by Country (2021-2026) & (Units) Table 119. North America IL-17 Inhibitors for Psoriasis Sales by Country (2027-2032) & (Units) Table 120. North America IL-17 Inhibitors for Psoriasis Sales Price by Country (2021-2026) & (US$/Unit) Table 121. North America IL-17 Inhibitors for Psoriasis Sales Price by Country (2027-2032) & (US$/Unit) Table 122. United States IL-17 Inhibitors for Psoriasis Revenue (2021-2032) & (US$ Million) Table 123. Canada IL-17 Inhibitors for Psoriasis Revenue (2021-2032) & (US$ Million) Table 124. Mexico IL-17 Inhibitors for Psoriasis Revenue (2021-2032) & (US$ Million) Table 125. Europe IL-17 Inhibitors for Psoriasis Revenue by Type (2021-2026) & (US$ Million) Table 126. Europe IL-17 Inhibitors for Psoriasis Revenue by Type (2027-2032) & (US$ Million) Table 127. Europe IL-17 Inhibitors for Psoriasis Sales by Type (2021-2026) & (Units) Table 128. Europe IL-17 Inhibitors for Psoriasis Sales by Type (2027-2032) & (Units) Table 129. Europe IL-17 Inhibitors for Psoriasis Sales Price by Type (2021-2026) & (US$/Unit) Table 130. Europe IL-17 Inhibitors for Psoriasis Sales Price by Type (2027-2032) & (US$/Unit) Table 131. Europe IL-17 Inhibitors for Psoriasis Revenue by Application (2021-2026) & (US$ Million) Table 132. Europe IL-17 Inhibitors for Psoriasis Revenue by Application (2027-2032) & (US$ Million) Table 133. Europe IL-17 Inhibitors for Psoriasis Sales by Application (2021-2026) & (Units) Table 134. Europe IL-17 Inhibitors for Psoriasis Sales by Application (2027-2032) & (Units) Table 135. Europe IL-17 Inhibitors for Psoriasis Sales Price by Application (2021-2026) & (US$/Unit) Table 136. Europe IL-17 Inhibitors for Psoriasis Sales Price by Application (2027-2032) & (US$/Unit) Table 137. Europe IL-17 Inhibitors for Psoriasis Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 138. Europe IL-17 Inhibitors for Psoriasis Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 139. Europe IL-17 Inhibitors for Psoriasis Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 140. Europe IL-17 Inhibitors for Psoriasis Sales by Country (2021 VS 2025 VS 2032) & (Units) Table 141. Europe IL-17 Inhibitors for Psoriasis Sales by Country (2021-2026) & (Units) Table 142. Europe IL-17 Inhibitors for Psoriasis Sales by Country (2027-2032) & (Units) Table 143. Europe IL-17 Inhibitors for Psoriasis Sales Price by Country (2021-2026) & (US$/Unit) Table 144. Europe IL-17 Inhibitors for Psoriasis Sales Price by Country (2027-2032) & (US$/Unit) Table 145. Germany IL-17 Inhibitors for Psoriasis Revenue (2021-2032) & (US$ Million) Table 146. France IL-17 Inhibitors for Psoriasis Revenue (2021-2032) & (US$ Million) Table 147. U.K. IL-17 Inhibitors for Psoriasis Revenue (2021-2032) & (US$ Million) Table 148. Italy IL-17 Inhibitors for Psoriasis Revenue (2021-2032) & (US$ Million) Table 149. Russia IL-17 Inhibitors for Psoriasis Revenue (2021-2032) & (US$ Million) Table 150. Spain IL-17 Inhibitors for Psoriasis Revenue (2021-2032) & (US$ Million) Table 151. Netherlands IL-17 Inhibitors for Psoriasis Revenue (2021-2032) & (US$ Million) Table 152. Switzerland IL-17 Inhibitors for Psoriasis Revenue (2021-2032) & (US$ Million) Table 153. Sweden IL-17 Inhibitors for Psoriasis Revenue (2021-2032) & (US$ Million) Table 154. Poland IL-17 Inhibitors for Psoriasis Revenue (2021-2032) & (US$ Million) Table 155. China IL-17 Inhibitors for Psoriasis Revenue by Type (2021-2026) & (US$ Million) Table 156. China IL-17 Inhibitors for Psoriasis Revenue by Type (2027-2032) & (US$ Million) Table 157. China IL-17 Inhibitors for Psoriasis Sales by Type (2021-2026) & (Units) Table 158. China IL-17 Inhibitors for Psoriasis Sales by Type (2027-2032) & (Units) Table 159. China IL-17 Inhibitors for Psoriasis Sales Price by Type (2021-2026) & (US$/Unit) Table 160. China IL-17 Inhibitors for Psoriasis Sales Price by Type (2027-2032) & (US$/Unit) Table 161. China IL-17 Inhibitors for Psoriasis Revenue by Application (2021-2026) & (US$ Million) Table 162. China IL-17 Inhibitors for Psoriasis Revenue by Application (2027-2032) & (US$ Million) Table 163. China IL-17 Inhibitors for Psoriasis Sales by Application (2021-2026) & (Units) Table 164. China IL-17 Inhibitors for Psoriasis Sales by Application (2027-2032) & (Units) Table 165. China IL-17 Inhibitors for Psoriasis Sales Price by Application (2021-2026) & (US$/Unit) Table 166. China IL-17 Inhibitors for Psoriasis Sales Price by Application (2027-2032) & (US$/Unit) Table 167. Asia IL-17 Inhibitors for Psoriasis Revenue by Type (2021-2026) & (US$ Million) Table 168. Asia IL-17 Inhibitors for Psoriasis Revenue by Type (2027-2032) & (US$ Million) Table 169. Asia IL-17 Inhibitors for Psoriasis Sales by Type (2021-2026) & (Units) Table 170. Asia IL-17 Inhibitors for Psoriasis Sales by Type (2027-2032) & (Units) Table 171. Asia IL-17 Inhibitors for Psoriasis Sales Price by Type (2021-2026) & (US$/Unit) Table 172. Asia IL-17 Inhibitors for Psoriasis Sales Price by Type (2027-2032) & (US$/Unit) Table 173. Asia IL-17 Inhibitors for Psoriasis Revenue by Application (2021-2026) & (US$ Million) Table 174. Asia IL-17 Inhibitors for Psoriasis Revenue by Application (2027-2032) & (US$ Million) Table 175. Asia IL-17 Inhibitors for Psoriasis Sales by Application (2021-2026) & (Units) Table 176. Asia IL-17 Inhibitors for Psoriasis Sales by Application (2027-2032) & (Units) Table 177. Asia IL-17 Inhibitors for Psoriasis Sales Price by Application (2021-2026) & (US$/Unit) Table 178. Asia IL-17 Inhibitors for Psoriasis Sales Price by Application (2027-2032) & (US$/Unit) Table 179. Asia IL-17 Inhibitors for Psoriasis Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 180. Asia IL-17 Inhibitors for Psoriasis Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 181. Asia IL-17 Inhibitors for Psoriasis Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 182. Asia IL-17 Inhibitors for Psoriasis Sales by Country (2021 VS 2025 VS 2032) & (Units) Table 183. Asia IL-17 Inhibitors for Psoriasis Sales by Country (2021-2026) & (Units) Table 184. Asia IL-17 Inhibitors for Psoriasis Sales by Country (2027-2032) & (Units) Table 185. Asia IL-17 Inhibitors for Psoriasis Sales Price by Country (2021-2026) & (US$/Unit) Table 186. Asia IL-17 Inhibitors for Psoriasis Sales Price by Country (2027-2032) & (US$/Unit) Table 187. Japan IL-17 Inhibitors for Psoriasis Revenue (2021-2032) & (US$ Million) Table 188. South Korea IL-17 Inhibitors for Psoriasis Revenue (2021-2032) & (US$ Million) Table 189. India IL-17 Inhibitors for Psoriasis Revenue (2021-2032) & (US$ Million) Table 190. Australia IL-17 Inhibitors for Psoriasis Revenue (2021-2032) & (US$ Million) Table 191. Taiwan IL-17 Inhibitors for Psoriasis Revenue (2021-2032) & (US$ Million) Table 192. Southeast Asia IL-17 Inhibitors for Psoriasis Revenue (2021-2032) & (US$ Million) Table 193. SAMEA IL-17 Inhibitors for Psoriasis Revenue by Type (2021-2026) & (US$ Million) Table 194. SAMEA IL-17 Inhibitors for Psoriasis Revenue by Type (2027-2032) & (US$ Million) Table 195. SAMEA IL-17 Inhibitors for Psoriasis Sales by Type (2021-2026) & (Units) Table 196. SAMEA IL-17 Inhibitors for Psoriasis Sales by Type (2027-2032) & (Units) Table 197. SAMEA IL-17 Inhibitors for Psoriasis Sales Price by Type (2021-2026) & (US$/Unit) Table 198. SAMEA IL-17 Inhibitors for Psoriasis Sales Price by Type (2027-2032) & (US$/Unit) Table 199. SAMEA IL-17 Inhibitors for Psoriasis Revenue by Application (2021-2026) & (US$ Million) Table 200. SAMEA IL-17 Inhibitors for Psoriasis Revenue by Application (2027-2032) & (US$ Million) Table 201. SAMEA IL-17 Inhibitors for Psoriasis Sales by Application (2021-2026) & (Units) Table 202. SAMEA IL-17 Inhibitors for Psoriasis Sales by Application (2027-2032) & (Units) Table 203. SAMEA IL-17 Inhibitors for Psoriasis Sales Price by Application (2021-2026) & (US$/Unit) Table 204. SAMEA IL-17 Inhibitors for Psoriasis Sales Price by Application (2027-2032) & (US$/Unit) Table 205. SAMEA IL-17 Inhibitors for Psoriasis Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 206. SAMEA IL-17 Inhibitors for Psoriasis Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 207. SAMEA IL-17 Inhibitors for Psoriasis Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 208. SAMEA IL-17 Inhibitors for Psoriasis Sales by Country (2021 VS 2025 VS 2032) & (Units) Table 209. SAMEA IL-17 Inhibitors for Psoriasis Sales by Country (2021-2026) & (Units) Table 210. SAMEA IL-17 Inhibitors for Psoriasis Sales by Country (2027-2032) & (Units) Table 211. SAMEA IL-17 Inhibitors for Psoriasis Sales Price by Country (2021-2026) & (US$/Unit) Table 212. SAMEA IL-17 Inhibitors for Psoriasis Sales Price by Country (2027-2032) & (US$/Unit) Table 213. Brazil IL-17 Inhibitors for Psoriasis Revenue (2021-2032) & (US$ Million) Table 214. Argentina IL-17 Inhibitors for Psoriasis Revenue (2021-2032) & (US$ Million) Table 215. Chile IL-17 Inhibitors for Psoriasis Revenue (2021-2032) & (US$ Million) Table 216. Colombia IL-17 Inhibitors for Psoriasis Revenue (2021-2032) & (US$ Million) Table 217. Peru IL-17 Inhibitors for Psoriasis Revenue (2021-2032) & (US$ Million) Table 218. Saudi Arabia IL-17 Inhibitors for Psoriasis Revenue (2021-2032) & (US$ Million) Table 219. Israel IL-17 Inhibitors for Psoriasis Revenue (2021-2032) & (US$ Million) Table 220. UAE IL-17 Inhibitors for Psoriasis Revenue (2021-2032) & (US$ Million) Table 221. Turkey IL-17 Inhibitors for Psoriasis Revenue (2021-2032) & (US$ Million) Table 222. Iran IL-17 Inhibitors for Psoriasis Revenue (2021-2032) & (US$ Million) Table 223. Egypt IL-17 Inhibitors for Psoriasis Revenue (2021-2032) & (US$ Million) Table 224. Key Raw Materials Table 225. Raw Materials Key Suppliers Table 226. IL-17 Inhibitors for Psoriasis Distributors List Table 227. IL-17 Inhibitors for Psoriasis Customers List Table 228. Research Programs/Design for This Report Table 229. Authors List of This Report Table 230. Secondary Sources Table 231. Primary Sources List of Figures Figure 1. IL-17 Inhibitors for Psoriasis Image Figure 2. Global IL-17 Inhibitors for Psoriasis Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global IL-17 Inhibitors for Psoriasis Market Size Share 2021 VS 2025 VS 2032 Figure 4. Ixekizumab Image Figure 5. Secukinumab Image Figure 6. Xeligekimab Image Figure 7. Vunakizumab Image Figure 8. Brodalumab Image Figure 9. Bimelizumab Image Figure 10. Other Image Figure 11. Global IL-17 Inhibitors for Psoriasis Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global IL-17 Inhibitors for Psoriasis Market Size Share 2021 VS 2025 VS 2032 Figure 13. Hospital and Clinic Image Figure 14. Pharmacy Image Figure 15. Other Image Figure 16. Global IL-17 Inhibitors for Psoriasis Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global IL-17 Inhibitors for Psoriasis Revenue (2021-2032) & (US$ Million) Figure 18. Global IL-17 Inhibitors for Psoriasis Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Region: 2025 Versus 2032 Figure 20. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Region (2021-2032) Figure 21. Global IL-17 Inhibitors for Psoriasis Sales (2021-2032) & (Units) Figure 22. Global IL-17 Inhibitors for Psoriasis Sales by Region: 2021 VS 2025 VS 2032 (Units) Figure 23. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Region (2021-2032) Figure 24. US & Canada & Mexico IL-17 Inhibitors for Psoriasis Sales YoY (2021-2032) & (Units) Figure 25. Europe IL-17 Inhibitors for Psoriasis Sales YoY (2021-2032) & (Units) Figure 26. China IL-17 Inhibitors for Psoriasis Sales YoY (2021-2032) & (Units) Figure 27. Asia (Excluding China) IL-17 Inhibitors for Psoriasis Sales YoY (2021-2032) & (Units) Figure 28. South America, Middle East and Africa IL-17 Inhibitors for Psoriasis Sales YoY (2021-2032) & (Units) Figure 29. Global IL-17 Inhibitors for Psoriasis Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 30. Global IL-17 Inhibitors for Psoriasis Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 31. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 32. Global IL-17 Inhibitors for Psoriasis Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 33. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Type (2021-2032) Figure 35. Global IL-17 Inhibitors for Psoriasis Sales by Type (2021 VS 2025 VS 2032) & (Units) Figure 36. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 37. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Type (2021-2032) Figure 38. Global IL-17 Inhibitors for Psoriasis Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 39. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Application (2021-2032) Figure 41. Global IL-17 Inhibitors for Psoriasis Sales by Application (2021 VS 2025 VS 2032) & (Units) Figure 42. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 43. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Application (2021-2032) Figure 44. North America IL-17 Inhibitors for Psoriasis Revenue Share by Type (2021-2032) Figure 45. North America IL-17 Inhibitors for Psoriasis Sales Share by Type (2021-2032) Figure 46. North America IL-17 Inhibitors for Psoriasis Revenue Share by Application (2021-2032) Figure 47. North America IL-17 Inhibitors for Psoriasis Sales Share by Application (2021-2032) Figure 48. North America IL-17 Inhibitors for Psoriasis Revenue Share by Country (2021-2032) Figure 49. North America IL-17 Inhibitors for Psoriasis Sales Share by Country (2021-2032) Figure 50. Europe IL-17 Inhibitors for Psoriasis Revenue Share by Type (2021-2032) Figure 51. Europe IL-17 Inhibitors for Psoriasis Sales Share by Type (2021-2032) Figure 52. Europe IL-17 Inhibitors for Psoriasis Revenue Share by Application (2021-2032) Figure 53. Europe IL-17 Inhibitors for Psoriasis Sales Share by Application (2021-2032) Figure 54. Europe IL-17 Inhibitors for Psoriasis Revenue Share by Country (2021-2032) Figure 55. Europe IL-17 Inhibitors for Psoriasis Sales Share by Country (2021-2032) Figure 56. China IL-17 Inhibitors for Psoriasis Revenue Share by Type (2021-2032) Figure 57. China IL-17 Inhibitors for Psoriasis Sales Share by Type (2021-2032) Figure 58. China IL-17 Inhibitors for Psoriasis Revenue Share by Application (2021-2032) Figure 59. China IL-17 Inhibitors for Psoriasis Sales Share by Application (2021-2032) Figure 60. Asia IL-17 Inhibitors for Psoriasis Revenue Share by Type (2021-2032) Figure 61. Asia IL-17 Inhibitors for Psoriasis Sales Share by Type (2021-2032) Figure 62. Asia IL-17 Inhibitors for Psoriasis Revenue Share by Application (2021-2032) Figure 63. Asia IL-17 Inhibitors for Psoriasis Sales Share by Application (2021-2032) Figure 64. Asia IL-17 Inhibitors for Psoriasis Revenue Share by Country (2021-2032) Figure 65. Asia IL-17 Inhibitors for Psoriasis Sales Share by Country (2021-2032) Figure 66. SAMEA IL-17 Inhibitors for Psoriasis Revenue Share by Type (2021-2032) Figure 67. SAMEA IL-17 Inhibitors for Psoriasis Sales Share by Type (2021-2032) Figure 68. SAMEA IL-17 Inhibitors for Psoriasis Revenue Share by Application (2021-2032) Figure 69. SAMEA IL-17 Inhibitors for Psoriasis Sales Share by Application (2021-2032) Figure 70. SAMEA IL-17 Inhibitors for Psoriasis Revenue Share by Country (2021-2032) Figure 71. SAMEA IL-17 Inhibitors for Psoriasis Sales Share by Country (2021-2032) Figure 72. IL-17 Inhibitors for Psoriasis Value Chain Figure 73. Manufacturing Cost Structure Figure 74. IL-17 Inhibitors for Psoriasis Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Years Considered Figure 78. Research Process Figure 79. Key Executives Interviewed

Scope & coverage.

Types
  • Ixekizumab
  • Secukinumab
  • Xeligekimab
  • Vunakizumab
  • Brodalumab
  • Bimelizumab
  • Other
Applications
  • Hospital and Clinic
  • Pharmacy
  • Other
Companies covered
  • UCB
  • Kyowa Kirin
  • LEO Pharma
  • Ortho Dermatologics
  • Jiangsu Hengrui Pharmaceuticals
  • Eli Lilly
  • Novartis
  • Chongqing Genrix Biopharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 IL-17 Inhibitors for Psoriasis Market by Type
  3. 1.2.1 Global IL-17 Inhibitors for Psoriasis Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Ixekizumab
  5. 1.2.3 Secukinumab
  6. 1.2.4 Xeligekimab
  7. 1.2.5 Vunakizumab
  8. 1.2.6 Brodalumab
  9. 1.2.7 Bimelizumab
  10. 1.2.8 Other
  11. 1.3 IL-17 Inhibitors for Psoriasis Market by Application
  12. 1.3.1 Global IL-17 Inhibitors for Psoriasis Market Size by Application, 2021 VS 2025 VS 2032
  13. 1.3.2 Hospital and Clinic
  14. 1.3.3 Pharmacy
  15. 1.3.4 Other
  16. 1.4 Assumptions and Limitations
  17. 1.5 Study Goals and Objectives
2 IL-17 Inhibitors for Psoriasis Market Dynamics
  1. 2.1 IL-17 Inhibitors for Psoriasis Industry Trends
  2. 2.2 IL-17 Inhibitors for Psoriasis Industry Drivers
  3. 2.3 IL-17 Inhibitors for Psoriasis Industry Opportunities and Challenges
  4. 2.4 IL-17 Inhibitors for Psoriasis Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global IL-17 Inhibitors for Psoriasis Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global IL-17 Inhibitors for Psoriasis Revenue by Region
  3. 3.2.1 Global IL-17 Inhibitors for Psoriasis Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global IL-17 Inhibitors for Psoriasis Revenue by Region (2021-2026)
  5. 3.2.3 Global IL-17 Inhibitors for Psoriasis Revenue by Region (2027-2032)
  6. 3.2.4 Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Region (2021-2032)
  7. 3.3 Global IL-17 Inhibitors for Psoriasis Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global IL-17 Inhibitors for Psoriasis Sales by Region
  9. 3.4.1 Global IL-17 Inhibitors for Psoriasis Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global IL-17 Inhibitors for Psoriasis Sales by Region (2021-2026)
  11. 3.4.3 Global IL-17 Inhibitors for Psoriasis Sales by Region (2027-2032)
  12. 3.4.4 Global IL-17 Inhibitors for Psoriasis Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global IL-17 Inhibitors for Psoriasis Revenue by Manufacturers
  2. 4.1.1 Global IL-17 Inhibitors for Psoriasis Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global IL-17 Inhibitors for Psoriasis Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global IL-17 Inhibitors for Psoriasis Sales by Manufacturers
  6. 4.2.1 Global IL-17 Inhibitors for Psoriasis Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global IL-17 Inhibitors for Psoriasis Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global IL-17 Inhibitors for Psoriasis Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global IL-17 Inhibitors for Psoriasis Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global IL-17 Inhibitors for Psoriasis Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global IL-17 Inhibitors for Psoriasis Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global IL-17 Inhibitors for Psoriasis Manufacturers, Product Type & Application
  13. 4.7 Global IL-17 Inhibitors for Psoriasis Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global IL-17 Inhibitors for Psoriasis Market CR5 and HHI
  16. 4.8.2 2025 IL-17 Inhibitors for Psoriasis Tier 1, Tier 2, and Tier 3
5 IL-17 Inhibitors for Psoriasis Market by Type
  1. 5.1 Global IL-17 Inhibitors for Psoriasis Revenue by Type
  2. 5.1.1 Global IL-17 Inhibitors for Psoriasis Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global IL-17 Inhibitors for Psoriasis Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Type (2021-2032)
  5. 5.2 Global IL-17 Inhibitors for Psoriasis Sales by Type
  6. 5.2.1 Global IL-17 Inhibitors for Psoriasis Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global IL-17 Inhibitors for Psoriasis Sales by Type (2021-2032) & (Units)
  8. 5.2.3 Global IL-17 Inhibitors for Psoriasis Sales Market Share by Type (2021-2032)
  9. 5.3 Global IL-17 Inhibitors for Psoriasis Price by Type
6 IL-17 Inhibitors for Psoriasis Market by Application
  1. 6.1 Global IL-17 Inhibitors for Psoriasis Revenue by Application
  2. 6.1.1 Global IL-17 Inhibitors for Psoriasis Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global IL-17 Inhibitors for Psoriasis Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Application (2021-2032)
  5. 6.2 Global IL-17 Inhibitors for Psoriasis Sales by Application
  6. 6.2.1 Global IL-17 Inhibitors for Psoriasis Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global IL-17 Inhibitors for Psoriasis Sales by Application (2021-2032) & (Units)
  8. 6.2.3 Global IL-17 Inhibitors for Psoriasis Sales Market Share by Application (2021-2032)
  9. 6.3 Global IL-17 Inhibitors for Psoriasis Price by Application
7 Company Profiles
  1. 7.1 UCB
  2. 7.1.1 UCB Company Information
  3. 7.1.2 UCB Business Overview
  4. 7.1.3 UCB IL-17 Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 UCB IL-17 Inhibitors for Psoriasis Product Portfolio
  6. 7.1.5 UCB Recent Developments
  7. 7.2 Kyowa Kirin
  8. 7.2.1 Kyowa Kirin Company Information
  9. 7.2.2 Kyowa Kirin Business Overview
  10. 7.2.3 Kyowa Kirin IL-17 Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Kyowa Kirin IL-17 Inhibitors for Psoriasis Product Portfolio
  12. 7.2.5 Kyowa Kirin Recent Developments
  13. 7.3 LEO Pharma
  14. 7.3.1 LEO Pharma Company Information
  15. 7.3.2 LEO Pharma Business Overview
  16. 7.3.3 LEO Pharma IL-17 Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 LEO Pharma IL-17 Inhibitors for Psoriasis Product Portfolio
  18. 7.3.5 LEO Pharma Recent Developments
  19. 7.4 Ortho Dermatologics
  20. 7.4.1 Ortho Dermatologics Company Information
  21. 7.4.2 Ortho Dermatologics Business Overview
  22. 7.4.3 Ortho Dermatologics IL-17 Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Ortho Dermatologics IL-17 Inhibitors for Psoriasis Product Portfolio
  24. 7.4.5 Ortho Dermatologics Recent Developments
  25. 7.5 Jiangsu Hengrui Pharmaceuticals
  26. 7.5.1 Jiangsu Hengrui Pharmaceuticals Company Information
  27. 7.5.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  28. 7.5.3 Jiangsu Hengrui Pharmaceuticals IL-17 Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Jiangsu Hengrui Pharmaceuticals IL-17 Inhibitors for Psoriasis Product Portfolio
  30. 7.5.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  31. 7.6 Eli Lilly
  32. 7.6.1 Eli Lilly Company Information
  33. 7.6.2 Eli Lilly Business Overview
  34. 7.6.3 Eli Lilly IL-17 Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Eli Lilly IL-17 Inhibitors for Psoriasis Product Portfolio
  36. 7.6.5 Eli Lilly Recent Developments
  37. 7.7 Novartis
  38. 7.7.1 Novartis Company Information
  39. 7.7.2 Novartis Business Overview
  40. 7.7.3 Novartis IL-17 Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Novartis IL-17 Inhibitors for Psoriasis Product Portfolio
  42. 7.7.5 Novartis Recent Developments
  43. 7.8 Chongqing Genrix Biopharmaceutical
  44. 7.8.1 Chongqing Genrix Biopharmaceutical Company Information
  45. 7.8.2 Chongqing Genrix Biopharmaceutical Business Overview
  46. 7.8.3 Chongqing Genrix Biopharmaceutical IL-17 Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Chongqing Genrix Biopharmaceutical IL-17 Inhibitors for Psoriasis Product Portfolio
  48. 7.8.5 Chongqing Genrix Biopharmaceutical Recent Developments
8 North America
  1. 8.1 North America IL-17 Inhibitors for Psoriasis Market Size by Type
  2. 8.1.1 North America IL-17 Inhibitors for Psoriasis Revenue by Type (2021-2032)
  3. 8.1.2 North America IL-17 Inhibitors for Psoriasis Sales by Type (2021-2032)
  4. 8.1.3 North America IL-17 Inhibitors for Psoriasis Price by Type (2021-2032)
  5. 8.2 North America IL-17 Inhibitors for Psoriasis Market Size by Application
  6. 8.2.1 North America IL-17 Inhibitors for Psoriasis Revenue by Application (2021-2032)
  7. 8.2.2 North America IL-17 Inhibitors for Psoriasis Sales by Application (2021-2032)
  8. 8.2.3 North America IL-17 Inhibitors for Psoriasis Price by Application (2021-2032)
  9. 8.3 North America IL-17 Inhibitors for Psoriasis Market Size by Country
  10. 8.3.1 North America IL-17 Inhibitors for Psoriasis Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America IL-17 Inhibitors for Psoriasis Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America IL-17 Inhibitors for Psoriasis Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe IL-17 Inhibitors for Psoriasis Market Size by Type
  2. 9.1.1 Europe IL-17 Inhibitors for Psoriasis Revenue by Type (2021-2032)
  3. 9.1.2 Europe IL-17 Inhibitors for Psoriasis Sales by Type (2021-2032)
  4. 9.1.3 Europe IL-17 Inhibitors for Psoriasis Price by Type (2021-2032)
  5. 9.2 Europe IL-17 Inhibitors for Psoriasis Market Size by Application
  6. 9.2.1 Europe IL-17 Inhibitors for Psoriasis Revenue by Application (2021-2032)
  7. 9.2.2 Europe IL-17 Inhibitors for Psoriasis Sales by Application (2021-2032)
  8. 9.2.3 Europe IL-17 Inhibitors for Psoriasis Price by Application (2021-2032)
  9. 9.3 Europe IL-17 Inhibitors for Psoriasis Market Size by Country
  10. 9.3.1 Europe IL-17 Inhibitors for Psoriasis Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe IL-17 Inhibitors for Psoriasis Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe IL-17 Inhibitors for Psoriasis Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China IL-17 Inhibitors for Psoriasis Market Size by Type
  2. 10.1.1 China IL-17 Inhibitors for Psoriasis Revenue by Type (2021-2032)
  3. 10.1.2 China IL-17 Inhibitors for Psoriasis Sales by Type (2021-2032)
  4. 10.1.3 China IL-17 Inhibitors for Psoriasis Price by Type (2021-2032)
  5. 10.2 China IL-17 Inhibitors for Psoriasis Market Size by Application
  6. 10.2.1 China IL-17 Inhibitors for Psoriasis Revenue by Application (2021-2032)
  7. 10.2.2 China IL-17 Inhibitors for Psoriasis Sales by Application (2021-2032)
  8. 10.2.3 China IL-17 Inhibitors for Psoriasis Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia IL-17 Inhibitors for Psoriasis Market Size by Type
  2. 11.1.1 Asia IL-17 Inhibitors for Psoriasis Revenue by Type (2021-2032)
  3. 11.1.2 Asia IL-17 Inhibitors for Psoriasis Sales by Type (2021-2032)
  4. 11.1.3 Asia IL-17 Inhibitors for Psoriasis Price by Type (2021-2032)
  5. 11.2 Asia IL-17 Inhibitors for Psoriasis Market Size by Application
  6. 11.2.1 Asia IL-17 Inhibitors for Psoriasis Revenue by Application (2021-2032)
  7. 11.2.2 Asia IL-17 Inhibitors for Psoriasis Sales by Application (2021-2032)
  8. 11.2.3 Asia IL-17 Inhibitors for Psoriasis Price by Application (2021-2032)
  9. 11.3 Asia IL-17 Inhibitors for Psoriasis Market Size by Country
  10. 11.3.1 Asia IL-17 Inhibitors for Psoriasis Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia IL-17 Inhibitors for Psoriasis Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia IL-17 Inhibitors for Psoriasis Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA IL-17 Inhibitors for Psoriasis Market Size by Type
  2. 12.1.1 SAMEA IL-17 Inhibitors for Psoriasis Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA IL-17 Inhibitors for Psoriasis Sales by Type (2021-2032)
  4. 12.1.3 SAMEA IL-17 Inhibitors for Psoriasis Price by Type (2021-2032)
  5. 12.2 SAMEA IL-17 Inhibitors for Psoriasis Market Size by Application
  6. 12.2.1 SAMEA IL-17 Inhibitors for Psoriasis Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA IL-17 Inhibitors for Psoriasis Sales by Application (2021-2032)
  8. 12.2.3 SAMEA IL-17 Inhibitors for Psoriasis Price by Application (2021-2032)
  9. 12.3 SAMEA IL-17 Inhibitors for Psoriasis Market Size by Country
  10. 12.3.1 SAMEA IL-17 Inhibitors for Psoriasis Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA IL-17 Inhibitors for Psoriasis Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA IL-17 Inhibitors for Psoriasis Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 IL-17 Inhibitors for Psoriasis Value Chain Analysis
  2. 13.1.1 IL-17 Inhibitors for Psoriasis Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 IL-17 Inhibitors for Psoriasis Production Mode & Process
  6. 13.2 IL-17 Inhibitors for Psoriasis Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 IL-17 Inhibitors for Psoriasis Distributors
  9. 13.2.3 IL-17 Inhibitors for Psoriasis Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst